NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

• Status: Active, not recruiting
• Trial end date: 2027-02-16
• Target enrollment: 0
• Participant gender: All

Summary

The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Akershus
• Collaborators: Haukeland University Hospital; Oslo University Hospital; South-Eastern Norway Regional Health Authority; St. Olavs Hospital; Sykehuset Innlandet HF; The Bergesen Foundation; University Hospital of North Norway; University of Bergen
• Treatments: Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• clinically and molecular verified classical A-T disease

Exclusion Criteria:

• less than 2 years of age

• participation in other on-going study

• pregnancy

• liver failure

• other severe medical conditions considered to set patient at risk